# A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

> **NCT03679767** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 121 (actual)

## Conditions studied

- Metastatic Non-small Cell Lung Cancer
- Locally Advanced Urothelial Cancer
- Metastatic Urothelial Cancer
- Unresectable Melanoma
- Metastatic Melanoma
- Locally Advanced Renal Cell Carcinoma
- Metastatic Clear-Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** Retifanlimab

## Key facts

- **NCT ID:** NCT03679767
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-09
- **Primary completion:** 2021-04-15
- **Final completion:** 2022-06-28
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2023-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03679767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03679767, "A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03679767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*